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Abstract
Aim: To investigate if the massive blood loss protocol ‘Code Red’ at a specialist cardiothoracic hospital was activated
according to local and national guidelines by a closed loop audit.
Methods: Electronic and paper patient care systems were searched in 2015 and 2018 to access records for the ‘Code
Red’ activations. Activation of the massive blood loss protocol was compared against the national standards set by The
British Committee for Standards in Haematology. The percentage of cases meeting each of the ten standards in the
specialist cardiac unit’s Protocol for the Management of Massive Blood Loss in Adults (adapted from the national
standards) were evaluated.
Results: ‘Code Red’ protocol was activated on 18 occasions in 2015 and nine occasions in 2018, representing just 0.83
and 0.26% of emergency surgeries, respectively. Between 2015 and 2018, there was a 6% increase of ‘Code Red’ cases
being appropriately activated, a 26% increase in the prompt notification of the haematology department upon activation,
alongside a 30% increase in the timely delivery of blood products, and a 25% decrease in the average amount of blood
transferred prior to ‘Code Red’ activation.
Conclusion: There has been an improvement in the standards of care and management of massive blood loss at this
specialist cardiac centre despite the target timeframe being reduced from 30 to 15min between 2015 and 2018.
Preparation for and anticipation of massive blood loss has likely decreased the number of incidences requiring ‘Code
Red’ activation, permitting delivery of safe patient care.
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Introduction
Our institution is an international centre of excellence in
cardiothoracic surgery, specifically reparative and
transplant, and intensive care. Blood loss and
transfusion are often associated with cardiac surgery
due to the invasiveness into the circulatory system, in
addition to the effect of cardiopulmonary bypass on
platelet function and associated coagulopathy (Kehara
et al 2014, Paparella et al 2004). Further, the need for
prophylactic high-dose anticoagulation increases the
risk of massive blood loss. Massive blood loss is a
serious clinical situation associated with worse patient
outcomes, including a higher mortality (Stainsby et al
2006b).
Guidelines from the British Committee for Standards in
Haematology (BCSH) (Hunt et al 2015, Stainsby et al
2006b) and the Association of Anaesthetists of Great
Britain and Ireland (Thomas et al 2010) stress the need
for effective recognition of haemorrhage and an effective
protocol. Designing a protocol requires a definition of
severe haemorrhage based on parameters monitored in
surgery as opposed to using retrospective measures.
The BCSH guidelines define massive blood loss as a
bleed that leads to a heart rate of more than 110beats/
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min and/or systolic blood pressure less than 90mmHg
(Hunt et al 2015), though hospitals may have
individually mandated criteria based on local expertise
and experience. Haemorrhage is a critical situation and
blood transfusion is a necessary part of treatment;
however, it is not without risks (Koch et al 2006).
Adverse outcomes stem from the known risks of
transfusion such as transfusion-related acute lung
injury, transfusion-related immunomodulation, infection,
and dilution coagulopathy. It was reported that the most
common adverse event following transfusion is a
haemolytic reaction caused by the giving of the wrong
blood to the patient (Stainsby et al 2006a). Moreover,
evidence shows that there is no difference in composite
end point (death from any cardiovascular cause)
between a restrictive and a liberal transfusion strategy
(Hajjar et al 2010, McIntyre et al 2004, Mazer et al
2017). This finding highlights the need for efficient
protocols that must be followed, particularly in acute and
emergency medicine. While massive haemorrhage is in
itself a risk factor for serious postoperative
complications and death, transfusions carry their own
independent risks and thus protocols must be installed,
followed, and activated only at the appropriate times.
Protocolisation in addition permits evaluation of the
treatment strategy.
The BCSH 2006 and 2015 (Hunt et al 2015, Stainsby
et al 2006b) guidelines on massive blood loss
management outline parameters that must be kept
within appropriate ranges and indicate which blood cell
components must be used to do so. The guidelines
stress the need for efficient communication between the
clinical teams and blood transfusion laboratories, as
well as the need for anticipation of scenarios that may
require thawing or delivery of blood products. This
inevitably requires thorough protocols.
The specialist cardiac unit has its own protocol
on massive blood loss in adult cardiothoracic
surgery, the unit's Protocol for the Management of
Massive Blood Loss in Adults ('Code Red') DN526, based
on the BCSH 2006 and 2015 guidelines. The protocol
aims to:
1. Maintain blood volume ensuring tissue oxygenation
2. Control bleeding by surgical intervention and use of
blood component therapy to stem the bleeding
3. Prevent secondary haemodilution
Activation of the 'Code Red' protocol leads to distribution
of 'Pack A', containing 4 units of red blood cells (RBCs)
and fresh frozen plasma (FFP) and one unit of platelets.
This mobilisation of blood products is done rapidly and
does not require blood test results or the
haematologists' consent.
We aimed to audit when 'Code Red' is activated
appropriately, according to the hospital-outlined criteria
defining massive blood loss. This was achieved via a
full-cycle, closed loop audit in 2015 and 2018. The
implications of this are two-fold: reducing morbidity and
reducing cost. Perioperative transfusion (regardless of
number of units or type of blood product) increases
postoperative mortality and risk of infection (Horvath
et al 2013, Koch et al 2006); thus, it follows that limiting
transfusion frequency to only when necessary not only
improves patient outcomes but also reduces treatment
costs.
Methods
A closed loop audit cycle was performed on the
appropriateness of 'Code Red' activation according to
hospital guidelines at the specialist cardiac unit, to
assess changes made since the initial audit in 2015.
The Laboratory Information System (electronic patient
records) was searched for 'Code Red' to establish the
number of times that 'Code Red' protocol was activated
in the 12 months of 2015. The results were then cross-
checked against paper request forms at the
haematology laboratory. To assess whether the protocol
was activated appropriately, we established the amount
of blood loss prior to activation of 'Code Red' by
searching the relevant patient care systems: SaferSleep
and Metavision (anaesthetic in-theatre records), and CIS
(Intensive Care Unit records). For each standard set by
the BCSH guidelines, the percentage of cases in which
that standard was met was calculated. One unit of RBCs
was assumed to be equivalent to 250–350ml.
The initial audit data collected in 2015 was analysed
and clinical stakeholders at the specialist cardiac unit
were informed of the results with the intention of
emphasising both awareness of 'Code Red' protocol and
importance of accurate and correct documentation of
steps within the protocol. Data collection (as above) was
repeated for the 12 months of 2018 and activation was
compared against the standards (The cardiac unit's
Protocol for the Management of Massive Blood Loss in
Adults ('Code Red') DN526), with four standards added
to reflect the update of the 2015 BCSH guidelines for
the Haematological Management of Major Haemorrhage
(Hunt et al 2015).
Data collection
During the 2015 audit cycle, there was absence of
documentation on the digital systems for six activations
and we were unable to locate the paper request forms.
These six activations were excluded from the data
analysis for 2015. There were no data missing from the
2018 cycle.
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Results
Patient demographics
There were 18 and nine patients in the 2015 and 2018
cohorts, respectively (Table 1). The mean age in 2015
was 57.9 years, a male:female ratio of 14:4, and BMI of
29.0. The 2018 cohort had a mean age of 57.3 years, a
male:female of 5:4, and a BMI of 22.8.
In 2015, 22% of 'Code Red' patients were undergoing an
elective operation, whereas this increased to 56% of the
cohort in 2018 (Table 2). Conversely, 'Code Red' patients
undergoing emergency surgery made up 67% of the
cohort in 2015; however, only 33% of the 2018 cohort.
The proportion of 'Code Red'-activated patients
undergoing each type of surgical procedure was different
between the cohorts. In the 2015 cohort, 67% of
patients were undergoing cardiac surgery, 17% thoracic,
and 17% transplant, whereas in 2018, the surgeries
consisted of 45% cardiac, 22% thoracic, 22% transplant,
and for one patient (11%) the type of surgery is
unknown.
Patient outcomes 24h after 'Code Red'
activation
Of the 18 patients in our 2015 cohort, 13 (72%)
recovered in the intensive care unit (ICU), one patient
(6%) died within 24h of 'Code Red' activation. A further
three patients (18%) died in the subsequent
postoperative days (Table 3). In 2018, seven patients
(78%) recovered in ICU, whereas two (22%) died during
the 24h post-protocol. One patient who died had been
admitted to the cardiac unit for extra-corporal
membrane oxygenation following multiorgan failure of
an unknown aetiology and died in theatre. The second
patient was admitted for pneumonectomy but returned
to theatre within 12h of the first operation for re-
exploration given suspected bleeding. 'Code Red' was
activated postoperatively on return to the ward; however,
the patient died before blood could be transfused.
Criteria for massive blood loss
Comparison of the percentage of cases in which each
standard was achieved is shown in Table 4. The average
amount of blood transfused prior to activation reduced
from 10.1 units in 2015 to 7.6 units in 2018, and our
results show that on re-audit 'Code Red' was activated in
line with protocol 89% of the time, an improvement of
6%. We also noticed an increase of 26% in the
proportion of cases in which haematology consultants
were informed of the 'Code Red' activation (and thus
their ability to prepare Pack B for request in the event of
continued bleeding), and a 30% increase in the timely
receipt of blood products after 'Code Red' activation. We
note that in 56% of cases in 2018, blood products were
received in under 10min (Table 5). The use of the
minimum required number of blood products decreased
by 66.6%, however.
Discussion
The aim of the audit was to evaluate whether criteria for
'Code Red' activation were met, and whether our 2015
audit affected appropriateness of protocol activation. We
found that the specialist cardiac unit performed well,
with the protocol appropriately activated 89% of the time
in 2018. There was also an improvement in timely
product preparation: products distributed within 30min
from 'Code Red' activation improved dramatically from
46 to 75%, despite the change in audit standards in
2018 to a new goal of having products ready within
15min (Table 4). This result might reflect the systematic
improvements which were introduced after first audit
cycle, such as a new process ensuring two bags of pre-
Table 1 Summary of ‘Code Red’ activation patient cohort
demographics for 2015 and 2018
Patient demographics 2015 2018
Mean age (years) 57.9 57.3
Male:female 14:4 5:4
Mean weight (kg) 88 70.1
Mean BMI 29.0 22.8
Total patients (n) 18 9
BMI: body mass index (kg/m2).
Table 2 Context of ‘Code Red’ activations in 2015 and 2018
‘Code Red’ activation 2015 2018
Total patients (n) 18 9
Admission
Immediately postoperative 13 8
Transplant 2 0
Cardiac (non-transplant) 1 0










ECMO: extracorporeal membrane oxygenation.
Table 3 Patient outcomes after ‘Code Red’ activation in 2015
and 2018
Patient outcomes 2015 2018
Recovered in ICU 13 7
Deaths within 24h 1 2
Deaths within one week 3 0
Unknown 1 0
Total patients (n) 18 9
ICU: intensive care unit.
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thawed plasma had to be kept in the lab. This has
increased the speed at which Pack A is made available
by the transfusion practitioners at the specialist cardiac
unit.
As expected due to appropriate planning prior to surgery,
there are lower rates of 'Code Red' activation in elective
operations than emergency operations for both audited
years (2015 and 2018). In 2015, at the specialist
cardiac unit there were a total of 1442 emergency
surgeries and 2878 elective surgeries performed (Table
6). 'Code Red' protocol was activated in 0.83% of
emergency surgeries but only in 0.14% of elective
surgeries. The total number of surgeries remained
similar in 2018, with 1144 emergency and 2897
elective surgeries performed; however, the proportion of
'Code Red' activation changed to 0.26 and 0.17%,
respectively. Preparation for surgery involves ordering
appropriate blood products as well as patient
optimisation in the case of any known coagulopathies
(such as haemophilia). The high standards of care at the
cardiac unit involving meticulous pre-planning in
anticipation of massive blood loss also potentially
explains the low number of 'Code Red' activations, which
could possibly be a gross underestimate of massive
blood loss occurrence. Indeed, after presentation of our
2015 audit cycle to the department, it was decided that
the specialist cardiac unit would move towards
individual clinicians' discretion to activate the protocol.
This flexibility and preparation should be seen as an
encouraging finding, indicating that forward planning
and excellent haematologist support limits the need for
the activation of such a protocol as timely supply of
blood products and expert advice is still readily
available. In 2018, only three of the nine patients
(standard V, Table 4) had a 'classic' Pack A (RBCs:FFP:
platelets in the ratio 4:4:1) issued (Figure 1). The
remaining patients all had customised packs, with one
patient having only two cryoprecipitate and one pack of
platelet issued in Pack A. This patient-specific response
accounts for why the standard was only met in 33% of
activations. The reduction in RBC pack transfusion and
increased 'personalised transfusion' is supported by
high-quality evidence: an observational cohort study of
11,963 patients undergoing cardiac surgery found that
RBC transfusion increased the risk of all postoperative
adverse events, and that morbidity increased
incrementally with each additional RBC unit transfused
(Koch et al 2006). Two randomised controlled trials in
which RBC transfusion protocol was purposefully
triggered at more restrictive thresholds found that
Table 4 The percentage of ‘Code Red’ activations in 2015 and 2018 that met each of the ten standards in the unit’s Protocol for the
Management of Massive Blood Loss in Adults
Standard Description
Cases meeting standard (n, %)
2015 2018
I Major blood loss condition fulfilled before activation of ‘Code Red’ 83.3 88.9
II Haematology informed in under 10min 54.5 80
III Products received within 30min of ‘Code Red’ activation 45.5 75
IV Transport and transfusion within 15min once products are readya 40 50
V Minimum number of products issued 100 33.3
VI If patient is on bypass, platelets should not be issued in Pack A 62.5 100
VII Hb maintained above 80 after transfusion b 57.1
VIII Acidosis actively managed to keep base excess above 5 b 71.4
IX Further dose of TXA after ‘Code Red’ activation b 14.3
X Samples sent for FBC and coagulation after every 3–5 units of blood transfused b 85.7
FBC: full blood count; Hb: haemoglobin; TXA: tranexamic acid.
aStandard IV – time was reduced from 30 to 15min due to labs carrying two defrosted units of FFP.
bStandards VII–X were not part of the 2015 audit and added to the unit’s Protocol in response to the 2015 update of the BCSH guidelines.
Table 5 Number of units of red blood cells transfused prior to
‘Code Red’ activation and the period of time, in minutes, from
activation to products being received, in the 2018 cohort. A unit
















RBC: red blood cell.
Table 6 Total number of surgeries at the specialist cardiac unit
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Figure 1 ‘Code Red’ Protocol
APPT: ; BP: ; FBC: full blood count; FFP: fresh frozen plasma; ICU: intensive care unit; IV: ; MH: ; PT: ; RBC: red blood cell;
RR: .
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increasingly strict thresholds did not negatively impact
patient outcomes when compared to cases where a
liberal approach to transfusion was used (Hajjar et al
2010, Mazer et al 2017). Furthermore, the ratio itself of
blood products transfused has been seen to affect
outcomes: a higher plasma:RBC ratio was shown to
lower mortality and organ dysfunction (Delaney et al
2017), and transfusion of a 1:1:1 ratio of plasma:
platelets:RBCs led to faster haemostasis than a 1:1:2
ratio (Holcomb et al 2015). As well as adverse
cardiovascular effects, another study demonstrated that
each RBC unit also increases crude risk of infection by
29% (Horvath et al 2013).
Our audit of the 'Code Red' guidelines is most limited by
the small sample size and incomplete data which, in
addition to the complexity of these patients, prevents
definitive conclusions on how 'Code Red' activation
correlates with mortality. Another limitation is that the
comparison of the 2015 and 2018 data, to assess
whether the change in BCSH guidelines affected the
success of the 'Code Red' protocol, was retrospective. A
prospective study with defined data collection points,
including functional outcome, would provide more data
to ascertain if there is a correlation between 'Code Red'
activation and mortality.
Although none of the patients in the 2018 cohort
weighed >85kg, the BCSH 2015 guidelines recommend
dosing FFP based on weight (15–20ml/kg), meaning
patients administered with a standard Pack A would be
under-dosed with FFP. There was no field in which to
record patient weight on the previous 'Code Red' paper
forms and this has now been changed. As such, we have
adapted the protocol to issue FFP based on weight.
There is also discussion about predictors for massive
blood loss. Thromboelastometry and
thromboelastography are two point-of-care tests that
monitor coagulation. A meta-analysis found that use of
these two measures during blood loss management led
to a fall in blood transfusion as well as a lower risk of re-
exploration surgery indicated by postoperative
haemorrhage (Deppe et al 2016). These results were
repeated when such testing was combined with
coagulation factor administration (G€orlinger 2011) and
integrated within a management algorithm (Karkouti
et al 2004).
Finally, establishing a universal definition of massive
blood loss may improve protocols worldwide by enabling
systematic reviews of papers describing potential
developments in the management of perioperative
blood loss, which for now are limited by the range of
definitions and criteria of massive blood loss. It may also
increase preparedness through opening the possibility
of predictive tool development and clinicians' confidence
to engage protocols.
To conclude, the massive blood loss protocol 'Code Red'
at the specialist cardiac unit continues to improve
towards meeting the standards set in the BCSH 2006
and 2015 guidelines while delivering often-personalised
care, and this preparedness may mean that fewer
instances of massive blood loss require activation of
'Code Red' protocol. We highlight the need for thorough
record-keeping and have adapted the 'Code Red' paper
forms such that FFP be given according to weight, in line
with BCSH 2015 guidelines. We encourage the
establishment of a universal definition of massive blood
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